Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease.
Areteia Therapeutics has raised $75.0M in total funding. The most recent round was Series A. The last funding was announced in February 2024.
Areteia Therapeutics's investors include ARCH Venture Partners, Sanofi, Bain Capital Life Sciences, Google Ventures, Maverick Capital.
Areteia Therapeutics is headquartered in Bernardsville, United States.
Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease.
Areteia Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Areteia Therapeutics — Funding & Investors." VCBacked, February 13, 2024, https://www.vcbacked.co/company/areteia-therapeutics. Accessed October 23, 2026.
VCBacked. (2024). Areteia Therapeutics — Funding & Investors. Retrieved October 23, 2026, from https://www.vcbacked.co/company/areteia-therapeutics
{{cite web |title=Areteia Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/areteia-therapeutics |website=VCBacked |access-date=October 23, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated